Clinical (and hematological) outcome of patients with VEXAS syndrome treated with JAKi. (A) Kaplan-Meier representation of the time to next treatment in patients treated by ruxolitinib or other JAKi. (B) Prednisone dose (percentage of baseline) after 1, 3, and 6 months in patients treated with ruxolitinib or other JAKi. (C-D) Hemoglobin and platelet count evolution at baseline and after 1 and 3 months of ruxolitinib in patients treated with ruxolitinib or other JAKi. (E) UBA1 fish plot of 2 patients treated with ruxolitinib.